Advertisement
Singapore markets open in 5 hours 56 minutes
  • Straits Times Index

    3,410.81
    -29.07 (-0.85%)
     
  • S&P 500

    5,567.19
    +30.17 (+0.54%)
     
  • Dow

    39,375.87
    +67.87 (+0.17%)
     
  • Nasdaq

    18,352.76
    +164.46 (+0.90%)
     
  • Bitcoin USD

    57,124.92
    -677.98 (-1.17%)
     
  • CMC Crypto 200

    1,185.07
    -23.62 (-1.95%)
     
  • FTSE 100

    8,203.93
    -37.33 (-0.45%)
     
  • Gold

    2,399.80
    +30.40 (+1.28%)
     
  • Crude Oil

    83.44
    -0.44 (-0.52%)
     
  • 10-Yr Bond

    4.2720
    -0.0830 (-1.91%)
     
  • Nikkei

    40,912.37
    -1.23 (-0.00%)
     
  • Hang Seng

    17,799.61
    -228.69 (-1.27%)
     
  • FTSE Bursa Malaysia

    1,611.02
    -5.73 (-0.35%)
     
  • Jakarta Composite Index

    7,253.37
    +32.48 (+0.45%)
     
  • PSE Index

    6,492.75
    -14.74 (-0.23%)
     

Compared to Estimates, Tabula Rasa Healthcare (TRHC) Q2 Earnings: A Look at Key Metrics

Tabula Rasa Healthcare (TRHC) reported $90.04 million in revenue for the quarter ended June 2023, representing a year-over-year increase of 24%. EPS of $0.05 for the same period compares to -$0.32 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $88.82 million, representing a surprise of +1.37%. The company delivered an EPS surprise of +135.71%, with the consensus EPS estimate being -$0.14.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

ADVERTISEMENT

Here is how Tabula Rasa Healthcare performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Medication census: 21070 million versus the two-analyst average estimate of 20987.06 million.

  • Total PACE census: 55804 million versus 55819.59 million estimated by two analysts on average.

  • Technology-enabled solutions census: 55804 million versus the two-analyst average estimate of 55819.59 million.

  • Revenue- Technology-enabled solutions revenue: $20.41 million versus the four-analyst average estimate of $18.35 million.

  • Revenue- Medication revenue: $69.63 million versus the four-analyst average estimate of $70.31 million.

View all Key Company Metrics for Tabula Rasa Healthcare here>>>

Shares of Tabula Rasa Healthcare have returned +0.3% over the past month versus the Zacks S&P 500 composite's +0.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Tabula Rasa Healthcare (TRHC) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research